# Mild, Moderate and Severe Renal Impairment Study

> **NCT02219516** · PHASE1 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** RDEA3170

## Key facts

- **NCT ID:** NCT02219516
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-01
- **Primary completion:** 2015-10-30
- **Final completion:** 2016-05-13
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219516, "Mild, Moderate and Severe Renal Impairment Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02219516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*